Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about GLYMPHATIC SYSTEM: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | GLYMPHATIC SYSTEM |
Knowledge base pages for this entity
graph TD
GLYMPHATIC_SYSTEM["GLYMPHATIC SYSTEM"]
GLYMPHATIC_SYSTEM -->|"mediates"| Brain_Interstitial_Solute_Clea["Brain Interstitial Solute Clearance"]
GLYMPHATIC_SYSTEM -->|"involved_in"| NEURODEGENERATION["NEURODEGENERATION"]
GLYMPHATIC_SYSTEM -->|"involved_in"| Blood_Brain_Barrier["Blood-Brain Barrier"]
AQP4["AQP4"] -->|"involved_in"| GLYMPHATIC_SYSTEM
Aquaporin_4["Aquaporin-4"] -->|"participates in"| GLYMPHATIC_SYSTEM| Target | Relation | Type | Str |
|---|---|---|---|
| EXTRACELLULAR TAU | associated_with | protein | 0.95 |
| Idiopathic Normal Pressure Hydrocephalus | associated_with | disease | 0.95 |
| TAU | associated_with | protein | 0.95 |
| Alzheimer'S Disease | involved_in | disease | 0.95 |
| Brain Metabolic Waste Clearance | mediates | process | 0.95 |
| Alzheimer's Disease | associated_with | disease | 0.95 |
| Brain Tissue Homeostasis | associated_with | process | 0.90 |
| Brain Interstitial Solutes | removes | molecule | 0.90 |
| Brain Interstitial Solute Clearance | mediates | process | 0.90 |
| macromolecule clearance | involved_in | process | 0.90 |
| AMYLOID BETA | transports | protein | 0.90 |
| Cerebrospinal Fluid Influx | mediates | process | 0.90 |
| TAU | transports | protein | 0.90 |
| Amyloid-β accumulation | regulates | phenotype | 0.90 |
| Amyloid-beta | involved_in | compound | 0.90 |
| Cerebral Edema | involved_in | disease | 0.90 |
| Beta-Amyloid Clearance | mediates | process | 0.88 |
| Central Nervous System Disorders | involved_in | disease | 0.85 |
| cerebral edema | regulates | disease | 0.85 |
| NEURODEGENERATION | involved_in | entity | 0.85 |
| Deep Cervical Lymph Nodes | associated_with | cell_type | 0.85 |
| Amyloid-Beta Accumulation | associated_with | process | 0.80 |
| neurodegeneration | regulates | process | 0.80 |
| Alzheimer's disease | impaired_in | disease | 0.80 |
| Alzheimer's disease | predicts | disease | 0.80 |
| tau | prevents | protein | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Physical exercise | associated_with | process | 0.95 |
| Sleep-wake cycle | regulates | process | 0.95 |
| AQP4 | involved_in | entity | 0.95 |
| Astrocyte | involved_in | cell_type | 0.95 |
| AQP4 | associated_with | protein | 0.95 |
| Β-Hydroxybutyrate | associated_with | compound | 0.95 |
| AQP4 | component_of | protein | 0.95 |
| BHB | associated_with | compound | 0.90 |
| Aquaporin-4 | associated_with | protein | 0.90 |
| Perivascular Channels | mediates | brain_region | 0.90 |
| Aquaporin-4 | participates_in | protein | 0.90 |
| 36917314 | removes | paper | 0.90 |
| 36917314 | removes | paper | 0.90 |
| Astrocytic calcium signaling | modulates | process | 0.85 |
| Cerebrospinal Fluid Dynamics | regulates | process | 0.85 |
| Sleep Disturbance | regulates | phenotype | 0.80 |
| AQP4 | regulates | gene | 0.80 |
| TGN-020 | regulates | compound | 0.80 |
| AQP4 | enables | gene | 0.80 |
| Ketogenic Diet | modulates | drug | 0.75 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Glymphatic System-Enhanced Antibody Clearance Reversal | 0.537 | neurodegeneration | Blood-brain barrier transport mechanisms |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 8 hypotheses Top: 0.947
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multi [PMID:40773034] | Leitner U, Chew SH, Blanch J, Viswanatha | J Neurol | 2025 | 1 |
| B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum [PMID:39222408] | Bennett JL, Pittock SJ, Paul F, Kim HJ, | Ann Clin Transl Neurol | 2024 | 1 |
| Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic str [PMID:34530847] | Carnero Contentti E, Correale J | J Neuroinflammation | 2021 | 1 |
| Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neur [PMID:41881459] | Filippatou AG, Gakis G, Bacchetti A, Kim | Neurology(R) neuroimmunology & | 2026 | 0 |
| β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708] | Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et | Acta Pharmacol Sin | 2026 | 0 |
| CCR2 knockdown attenuates post-hemorrhagic hydrocephalus and improves glymphatic [PMID:41539459] | Deng H, Zhang S, Wang H, Liu X, Zhong K | Exp Neurol | 2026 | 0 |
| Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955] | Qi F, Lennon VA, Zhao S, Guo Y, Ding H e | J Clin Invest | 2026 | 0 |
| Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198] | Bennett JL, Bhattacharyya S, Zabeti A, L | Mult Scler | 2026 | 0 |
| NMOSD and MOGAD: Updates on diagnostic criteria. [PMID:41927386] | Marignier R, Leal Rato M | Rev Neurol (Paris) | 2026 | 0 |
| Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387] | Elosua-Bayés I, Cobo-Calvo A | Rev Neurol (Paris) | 2026 | 0 |
| Recurrent aquaporin 4-immunoglobulin G-positive neuromyelitis optica spectrum di [PMID:41915816] | Jiang X, Chen J, Wen Y, Yuan L, Zhang J | The Journal of international m | 2026 | 0 |
| Glymphatic System Dysfunction in Central Nervous System Diseases. [PMID:41792880] | Zahran A, Abu-Khazneh O, Bdair M, Hajjeh | CNS neuroscience & therapeutic | 2026 | 0 |
| Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD [PMID:41921124] | Tournier A, Gavoille A, Pique J, Levraut | Neurology | 2026 | 0 |
| Mapping the Brain's Glymphatic System. [PMID:41751308] | Voumvourakis K, Thomaidis NS, Tsiodras S | Biomedicines | 2026 | 0 |
| Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling [PMID:41843863] | Deschamps R, Papeix C, Demortiere S, Lar | Neurology | 2026 | 0 |
| A compound pulsed magnetic field achieves superior cognitive benefits against Al [PMID:41856031] | Wang X, Wang X, Zhao H, Zhao C, Wang P, | Neurotherapeutics : the journa | 2026 | 0 |
| Physical exercise as a non-pharmacological strategy to enhance glymphatic functi [PMID:41676384] | Ghayourvahdat A, Azimizonuzi H, Ahmed M | IBRO neuroscience reports | 2026 | 0 |
| Brominated flame retardants in black plastic kitchen utensils: Concentrations an [PMID:28847134] | ["Kuang J", "Abdallah M", "Harrad S"] | The Science of the total envir | 2018 | 0 |
| Genome-wide association study of 40,000 individuals identifies two novel loci as [PMID:27329760] | ["Hou L", "Bergen S", "Akula N", "Song J | Human molecular genetics | 2016 | 0 |
| Immunohistochemical evidence for the association between attenuated mTOR signali [PMID:25186104] | ["Saito R", "Yanai M", "Miki Y", "Fukasa | The Tohoku journal of experime | 2014 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning GLYMPHATIC SYSTEM in their description or question text
No additional research found